Similarly, when we treated orthotopically implanted syngeneic GL261 tumors with systemically administered anti-CD47 antibody, we noted a small tumor growth inhibitory effect and survival benefit (Fig. 1c, d). This evidence concerns the gene CD47 and neoplasm.